Our research results validated the tight association between neuroinflammation and CRF depression-like behavior, and FG can improve CRF depression-like behavior (Figure 10) by inhibiting the expression of iNOS and COX2 in the prefrontal cortex and hippocampus of CRF model mice (Figure 11), which is consistent with the results of the BV2 cell experiments above and proves the therapeutic effect of FG on CRF depression-like behavior. The gene discussed is PTGS2; the disease is major depressive disorder.